These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 7834215

  • 1. Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors.
    Boyer JL, Zohn IE, Jacobson KA, Harden TK.
    Br J Pharmacol; 1994 Oct; 113(2):614-20. PubMed ID: 7834215
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of ecto-ATPase by PPADS, suramin and reactive blue in endothelial cells, C6 glioma cells and RAW 264.7 macrophages.
    Chen BC, Lee CM, Lin WW.
    Br J Pharmacol; 1996 Dec; 119(8):1628-34. PubMed ID: 8982511
    [Abstract] [Full Text] [Related]

  • 3. The use of antagonists to characterize the receptors mediating depolarization of the rat isolated vagus nerve by alpha, beta-methylene adenosine 5'-triphosphate.
    Trezise DJ, Kennedy I, Humphrey PP.
    Br J Pharmacol; 1994 May; 112(1):282-8. PubMed ID: 8032652
    [Abstract] [Full Text] [Related]

  • 4. The P2Y purinoceptor in rat brain microvascular endothelial cells couple to inhibition of adenylate cyclase.
    Webb TE, Feolde E, Vigne P, Neary JT, Runberg A, Frelin C, Barnard EA.
    Br J Pharmacol; 1996 Dec; 119(7):1385-92. PubMed ID: 8968547
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of P2-purinoceptor antagonists at two relaxation-mediating P2-purinoceptors in guinea-pig taenia coli.
    Bültmann R, Dudeck O, Starke K.
    Naunyn Schmiedebergs Arch Pharmacol; 1996 Mar; 353(4):445-51. PubMed ID: 8935712
    [Abstract] [Full Text] [Related]

  • 6. Potent agonist action of 2-thioether derivatives of adenine nucleotides at adenylyl cyclase-linked P2Y-purinoceptors.
    Boyer JL, O'Tuel JW, Fischer B, Jacobson KA, Harden TK.
    Br J Pharmacol; 1995 Nov; 116(6):2611-6. PubMed ID: 8590978
    [Abstract] [Full Text] [Related]

  • 7. PPADS and suramin as antagonists at cloned P2Y- and P2U-purinoceptors.
    Charlton SJ, Brown CA, Weisman GA, Turner JT, Erb L, Boarder MR.
    Br J Pharmacol; 1996 Jun; 118(3):704-10. PubMed ID: 8762097
    [Abstract] [Full Text] [Related]

  • 8. ADP-evoked phospholipase C stimulation and adenylyl cyclase inhibition in glioma C6 cells occur through two distinct nucleotide receptors, P2Y(1) and P2Y(12).
    Czajkowski R, Lei L, Sabała P, Barańska J.
    FEBS Lett; 2002 Feb 27; 513(2-3):179-83. PubMed ID: 11904146
    [Abstract] [Full Text] [Related]

  • 9. Co-existence of P2Y-and PPADS-insensitive P2U-purinoceptors in endothelial cells from adrenal medulla.
    Mateo J, Miras-Portugal MT, Castro E.
    Br J Pharmacol; 1996 Nov 27; 119(6):1223-32. PubMed ID: 8937727
    [Abstract] [Full Text] [Related]

  • 10. A novel P2-purinoceptor expressed by a subpopulation of astrocytes from the dorsal spinal cord of the rat.
    Ho C, Hicks J, Salter MW.
    Br J Pharmacol; 1995 Dec 27; 116(7):2909-18. PubMed ID: 8680724
    [Abstract] [Full Text] [Related]

  • 11. Fidelity in functional coupling of the rat P2Y1 receptor to phospholipase C.
    Schachter JB, Boyer JL, Li Q, Nicholas RA, Harden TK.
    Br J Pharmacol; 1997 Nov 27; 122(6):1021-4. PubMed ID: 9401764
    [Abstract] [Full Text] [Related]

  • 12. Design and pharmacology of selective P2-purinoceptor antagonists.
    Lambrecht G.
    J Auton Pharmacol; 1996 Dec 27; 16(6):341-4. PubMed ID: 9131412
    [Abstract] [Full Text] [Related]

  • 13. Second messenger cascade specificity and pharmacological selectivity of the human P2Y1-purinoceptor.
    Schachter JB, Li Q, Boyer JL, Nicholas RA, Harden TK.
    Br J Pharmacol; 1996 May 27; 118(1):167-73. PubMed ID: 8733591
    [Abstract] [Full Text] [Related]

  • 14. PPADS: an antagonist at endothelial P2Y-purinoceptors but not P2U-purinoceptors.
    Brown C, Tanna B, Boarder MR.
    Br J Pharmacol; 1995 Nov 27; 116(5):2413-6. PubMed ID: 8581277
    [Abstract] [Full Text] [Related]

  • 15. Identification of competitive antagonists of the P2Y1 receptor.
    Boyer JL, Romero-Avila T, Schachter JB, Harden TK.
    Mol Pharmacol; 1996 Nov 27; 50(5):1323-9. PubMed ID: 8913364
    [Abstract] [Full Text] [Related]

  • 16. Functional characterisation of P2 purinoceptors in PC12 cells by measurement of radiolabelled calcium influx.
    Michel AD, Grahames CB, Humphrey PP.
    Naunyn Schmiedebergs Arch Pharmacol; 1996 Nov 27; 354(5):562-71. PubMed ID: 8938653
    [Abstract] [Full Text] [Related]

  • 17. Discrimination by PPADS between endothelial P2Y- and P2U-purinoceptors in the rat isolated mesenteric arterial bed.
    Ralevic V, Burnstock G.
    Br J Pharmacol; 1996 May 27; 118(2):428-34. PubMed ID: 8735648
    [Abstract] [Full Text] [Related]

  • 18. Discrimination between two types of P2 purinoceptors by suramin in rat hepatocytes.
    Tomura H, Okajima F, Kondo Y.
    Eur J Pharmacol; 1992 Aug 03; 226(4):363-5. PubMed ID: 1397062
    [Abstract] [Full Text] [Related]

  • 19. P2-purinoceptors mediating spasm of the isolated uterus of the non-pregnant guinea-pig.
    Piper AS, Hollingsworth M.
    Br J Pharmacol; 1996 Apr 03; 117(8):1721-9. PubMed ID: 8732282
    [Abstract] [Full Text] [Related]

  • 20. A molecularly identified P2Y receptor simultaneously activates phospholipase C and inhibits adenylyl cyclase and is nonselectively activated by all nucleoside triphosphates.
    Boyer JL, Delaney SM, Villanueva D, Harden TK.
    Mol Pharmacol; 2000 Apr 03; 57(4):805-10. PubMed ID: 10727529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.